Christopher R Kelly1, Paul S Teirstein2, Ian T Meredith3, Bruno Farah4, Christophe L Dubois5, Robert L Feldman6, Joseph Dens7, Nobuhisa Hagiwara8, Abram Rabinowitz9, Didier Carrié10, Vincent Pompili11, Alain Bouchard12, Shigeru Saito13, Dominic J Allocco14, Keith D Dawkins14, Gregg W Stone15. 1. Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York. 2. Scripps Clinic, La Jolla, California. 3. MonashHEART, Southern Health, Monash Medical Centre, Clayton, Victoria, Australia. 4. Clinique Pasteur-Toulouse, Toulouse, France. 5. University Hospital Leuven, Leuven, Belgium. 6. Mediquest Research at Munroe Regional Medical Center, Ocala, Florida. 7. Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium. 8. Tokyo Women's Medical University Hospital, Shinjuku, Tokyo, Japan. 9. TexSan Heart Hospital, San Antonio, Texas. 10. Université Paul Sabatier, Centre Hospitalier Universitaire Rangueil, Toulouse, France. 11. University of Nebraska Medical Center, Omaha, Nebraska. 12. Baptist Medical Center-Princeton, Birmingham, Alabama. 13. Shonan Kamakura General Hospital, Kanagawa, Japan. 14. Boston Scientific Corporation, Marlborough, Massachusetts. 15. Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York. Electronic address: gs2184@columbia.edu.
Abstract
OBJECTIVES: The authors sought to evaluate the final 5-year safety and effectiveness of the platinum-chromium everolimus-eluting stent (PtCr-EES) in the randomized trial, as well as in 2 single-arm substudies that evaluated PtCr-EES in small vessels (diameter <2.5 mm; n = 94) and long lesions (24 to 34 mm; n = 102). BACKGROUND: In the multicenter, randomized PLATINUM (PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions), the PtCr-EES was noninferior to the cobalt-chromium everolimus-eluting stent (CoCr-EES) at 1 year in 1,530 patients undergoing percutaneous coronary intervention. METHODS:Patients with 1 or 2 de novo coronary artery lesions (reference vessel diameter 2.50 to 4.25 mm, length ≤24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. All patients in the substudies received PtCr-EES. The primary endpoint was target lesion failure (TLF), a composite of target vessel-related cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization. RESULTS: In the randomized trial, the 5-year TLF rate was 9.1% for PtCr-EES and 9.3% for CoCr-EES (hazard ratio [HR]: 0.97; p = 0.87). Landmark analysis demonstrated similar TLF rates from discharge to 1 year (HR: 1.12; p = 0.70) and from 1 to 5 years (HR: 0.90; p = 0.63). There were no significant differences in the rates of cardiac death, myocardial infarction, target lesion or vessel revascularization, or stent thrombosis. PtCr-EES had 5-year TLF rates of 7.0% in small vessels and 13.6% in long lesions. CONCLUSIONS:PtCr-EES demonstrated comparable safety and effectiveness to CoCr-EES through 5 years of follow-up, with low rates of stent thrombosis and other adverse events. The 5-year event rates were also acceptable in patients with small vessels and long lesions treated with PtCr-EES. (The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions [PLATINUM]; NCT00823212; The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels [PLATINUM SV]; NCT01498692; The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions [PLATINUM LL]; NCT01500434).
RCT Entities:
OBJECTIVES: The authors sought to evaluate the final 5-year safety and effectiveness of the platinum-chromium everolimus-eluting stent (PtCr-EES) in the randomized trial, as well as in 2 single-arm substudies that evaluated PtCr-EES in small vessels (diameter <2.5 mm; n = 94) and long lesions (24 to 34 mm; n = 102). BACKGROUND: In the multicenter, randomized PLATINUM (PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions), the PtCr-EES was noninferior to the cobalt-chromium everolimus-eluting stent (CoCr-EES) at 1 year in 1,530 patients undergoing percutaneous coronary intervention. METHODS:Patients with 1 or 2 de novo coronary artery lesions (reference vessel diameter 2.50 to 4.25 mm, length ≤24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. All patients in the substudies received PtCr-EES. The primary endpoint was target lesion failure (TLF), a composite of target vessel-related cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization. RESULTS: In the randomized trial, the 5-year TLF rate was 9.1% for PtCr-EES and 9.3% for CoCr-EES (hazard ratio [HR]: 0.97; p = 0.87). Landmark analysis demonstrated similar TLF rates from discharge to 1 year (HR: 1.12; p = 0.70) and from 1 to 5 years (HR: 0.90; p = 0.63). There were no significant differences in the rates of cardiac death, myocardial infarction, target lesion or vessel revascularization, or stent thrombosis. PtCr-EES had 5-year TLF rates of 7.0% in small vessels and 13.6% in long lesions. CONCLUSIONS: PtCr-EES demonstrated comparable safety and effectiveness to CoCr-EES through 5 years of follow-up, with low rates of stent thrombosis and other adverse events. The 5-year event rates were also acceptable in patients with small vessels and long lesions treated with PtCr-EES. (The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions [PLATINUM]; NCT00823212; The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels [PLATINUM SV]; NCT01498692; The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions [PLATINUM LL]; NCT01500434).
Authors: Donald E Cutlip; Amit G Chhabra; Donald S Baim; Manish S Chauhan; Sachin Marulkar; Joseph Massaro; Ameet Bakhai; David J Cohen; Richard E Kuntz; Kalon K L Ho Journal: Circulation Date: 2004-08-30 Impact factor: 29.690
Authors: Lisette Okkels Jensen; Per Thayssen; Henrik Steen Hansen; Evald Høj Christiansen; Hans Henrik Tilsted; Lars Romer Krusell; Anton Boel Villadsen; Anders Junker; Knud Nørregaard Hansen; Anne Kaltoft; Michael Maeng; Knud Erik Pedersen; Steen Dalby Kristensen; Hans Erik Bøtker; Jan Ravkilde; Richardo Sanchez; Jens Aarøe; Morten Madsen; Henrik Toft Sørensen; Leif Thuesen; Jens Flensted Lassen Journal: Circulation Date: 2012-02-03 Impact factor: 29.690
Authors: Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes Journal: N Engl J Med Date: 2010-05-06 Impact factor: 91.245
Authors: Paul S Teirstein; Ian T Meredith; Robert L Feldman; A Charles Rabinowitz; Louis A Cannon; Tommy C Lee; Joseph Dens; Christophe L Dubois; Michael R Mooney; Vincent J Pompili; Shigeru Saito; Dominic J Allocco; Keith D Dawkins; Gregg W Stone Journal: Catheter Cardiovasc Interv Date: 2014-07-04 Impact factor: 2.692
Authors: Barry J O'Brien; Jon S Stinson; Steve R Larsen; Michael J Eppihimer; William M Carroll Journal: Biomaterials Date: 2010-02-23 Impact factor: 12.479
Authors: Lisette Okkels Jensen; Per Thayssen; Evald Høj Christiansen; Michael Maeng; Jan Ravkilde; Knud Nørregaard Hansen; Henrik Steen Hansen; Lars Krusell; Anne Kaltoft; Hans Henrik Tilsted; Klara Berencsi; Anders Junker; Jens Flensted Lassen Journal: J Am Coll Cardiol Date: 2016-02-23 Impact factor: 24.094
Authors: Gregg W Stone; Paul S Teirstein; Ian T Meredith; Bruno Farah; Christophe L Dubois; Robert L Feldman; Joseph Dens; Nobuhisa Hagiwara; Dominic J Allocco; Keith D Dawkins Journal: J Am Coll Cardiol Date: 2011-04-04 Impact factor: 24.094
Authors: Hemal Gada; Ajay J Kirtane; William Newman; Mark Sanz; James B Hermiller; Kenneth W Mahaffey; Donald E Cutlip; Krishnankutty Sudhir; Liming Hou; Kai Koo; Gregg W Stone Journal: JACC Cardiovasc Interv Date: 2013-11-13 Impact factor: 11.195
Authors: Clemens von Birgelen; Hanim Sen; Ming Kai Lam; Peter W Danse; Gillian A J Jessurun; Raymond W M Hautvast; Gert K van Houwelingen; Alexander R Schramm; R Melvyn Tjon Joe Gin; Johannes W Louwerenburg; Frits H A F de Man; Martin G Stoel; Marije M Löwik; Gerard C M Linssen; Salah A M Saïd; Mark B Nienhuis; Patrick M J Verhorst; Mounir W Z Basalus; Carine J M Doggen; Kenneth Tandjung Journal: Lancet Date: 2013-10-31 Impact factor: 79.321